Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA

Oral fostamatinib is an orally administered small molecule spleen tyrosine kinase (SYK) inhibitor approved for the treatment of adults with chronic immune thrombocytopenia (ITP) who have an inadequate response to a previous treatment. Fostamatinib has a unique mechanism of action, whereby its active...

Descripción completa

Detalles Bibliográficos
Autores principales: McKeage, Kate, Lyseng-Williamson, Katherine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Adis Drug Q&A
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223701/
https://www.ncbi.nlm.nih.gov/pubmed/30459507
http://dx.doi.org/10.1007/s40267-018-0551-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223701/
https://www.ncbi.nlm.nih.gov/pubmed/30459507
http://dx.doi.org/10.1007/s40267-018-0551-x

Ejemplares similares